Among these, the predicted binding of Celecoxib to PDK1 (−6.52 kcal/mol) in AD and ALS is particularly intriguing, as it suggests a potential mechanism for restoring mitochondrial bioenergetics by enhancing PDC activity. Here, PDC is linked to amyotrophic lateral sclerosis.